Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Mometasone furoate
Organon Pharma (UK) Ltd
D07AC13
Mometasone furoate
1mg/1gram
Cutaneous liquid
Cutaneous
No Controlled Drug Status
Valid as a prescribable product
BNF: 13040000; GTIN: 5012376019734
PACKAGE LEAFLET: INFORMATION FOR THE USER ELOCON® SCALP LOTION Mometasone Furoate READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See Section 4. WHAT IS IN THIS LEAFLET: 1. What Elocon is and what it is used for 2. What you need to know before you use Elocon 3. How to use Elocon 4. Possible side effects 5. How to store Elocon 6. Contents of the pack and other information 1. WHAT ELOCON IS AND WHAT IT IS USED FOR Elocon Scalp Lotion is one of a group of medicines called topical corticosteroids. It is classified as a “potent corticosteroid”. These medicines are put on the surface of the skin to reduce the redness and itchiness caused by certain skin problems. In adults and children, Elocon Scalp Lotion is used to reduce redness and itchiness caused by certain conditions affecting the scalp, called psoriasis or dermatitis. Psoriasis is a skin disease in which itchy, scaly, pink patches develop on the elbows, knees, scalp and other parts of the body. Dermatitis is a condition brought on by the skin reacting to outside agents e.g. detergents, causing the skin to become red and itchy. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE ELOCON Do not use Elocon if you have any of the following: Allergies (hypersensitivity) to mometasone furoate, or any of the other ingredients of this medicine (listed in section 6) or to other similar medicines Scalp problems as it could make them worse Chickenpox Shingles Warts Other skin infections Ulcerated skin Wounds Skin atrophy (thinning of the skin) Ask your Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Elocon 0.1% w/w Scalp Lotion 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Mometasone furoate 0.1% w/w Excipient with known effect Propylene glycol 30.0% w/w For full list of excipients see section 6.1. 3 PHARMACEUTICAL FORM Lotion 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Elocon Scalp Lotion is indicated for the treatment of inflammatory and pruritic manifestations of psoriasis and seborrhoeic dermatitis of the scalp. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Adults, including elderly patients and Children : _A few drops of Elocon Scalp Lotion should be applied to affected scalp sites, once daily; massage gently and thoroughly until the medication disappears. Use of topical corticosteroids in children should be limited to the least amount compatible with an effective therapeutic regimen and duration of treatment should be no more than 5 days. 4.3 CONTRAINDICATIONS Elocon Scalp Lotion is contraindicated in skin atrophy, bacterial (e.g. impetigo, pyodermas), viral (e.g. herpes simplex, herpes zoster and chickenpox, verrucae vulgares, condylomata acuminata, molluscum contagiosum) parasitical and fungal (e.g. candida or dermatophyte) infections of the scalp. Elocon should not be used on wounds or on skin which is ulcerated. Elocon Scalp Lotion should not be used in patients who are sensitive to mometasone furoate or to other corticosteroids or to any of the excipients listed in section 6.1. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE If irritation or sensitisation develop with the use of Elocon, treatment should be withdrawn and appropriate therapy instituted. Should an infection develop, use of an appropriate antifungal or antibacterial agent should be instituted. If a favourable response does not occur promptly, the corticosteroid should be discontinued until the infection is adequately controlled. Systemic absorption of topical corticosteriods can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential f Read the complete document